The Phase 3 failure has prompted Gilead Sciences and Arcus Biosciences to terminate a mid-stage study of their TIGIT asset in ...
Gilead Sciences and Arcus Biosciences’ domvanalimab, one of the last anti-TIGIT antibodies still standing, has failed another ...
Arcus Biosciences (RCUS) stock drops as the company halts a late-stage trial for a lung cancer drug developed with Gilead ...
Arcus Biosciences is discontinuing a phase 3 lung cancer trial it was conducting with Gilead Sciences. Arcus, an oncology company, said Monday it was ending the trial due to futility, meaning it doesn ...
Bill Grossman is leaving Arcus Biosciences to take up a position at Gilead, putting him in charge of the Big Pharma's collaboration with his former employers. Grossman is currently chief medical ...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...
Gilead Sciences (GILD 2.18%) and Arcus Biosciences (RCUS 4.04%) have signed a 10-year agreement to co-develop and co-commercialize the next-generation cancer therapeutics in Arcus' pipeline. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results